Women’s health drugmaker Meditrina seeks fresh funding

Endometriosis drugmaker Meditrina Pharmaceuticals wants to raise $500,000, according to a regulatory filing.

Meditrina, which is based in Ann Arbor, Michigan, is using patents from AstraZeneca to treat women’s health problems including endometriosis and uterine fibroids, which are abnormal growths or tumors that can cause pain and infertility. The company has completed Phase II trials on its two drugs – MPI-676 and MPI-674 – which treat endometriosis and abnormal uterine bleeding, respectively.

Its drugs stop the creation of aromatase, which typically creates estrogen.

The four-year-old company launched with about $4.4 million in funding provided through the state of Michigan.